论文部分内容阅读
一项来自于美国泌尿外科学会年会(AUA)的研究报告指出,小细胞尿路上皮癌患者膀胱切除后辅加化疗可有效改善其存活率。美国得克萨斯州休斯顿Anderson癌症研究中心生殖泌尿肿瘤科的助理教授Arlene Siefker-Radtke博士报道说,一项由26例患者参加且随访期为48个月的小规模Ⅱ期临床试验结果显示,术前接受化疗的患者总体存活率为68%,而单独手术未予以化疗的对照组患者则为30%～40%。Siefker-Radtke博士对此解释说,初步研究主要基于早期开展的一项回顾性调查研究数据,而此项研究结果证实手术后接受化学治疗的小细胞膀胱肿瘤患者的预后明显好于单独化疗者。
A study from the annual meeting of the American Urological Association (AUA) pointed out that adjuvant chemotherapy after cystectomy in patients with small cell urothelial carcinoma can effectively improve its survival rate. Dr. Arlene Siefker-Radtke, an assistant professor of genitourinary oncology at the Anderson Cancer Center in Houston, Texas, USA, reported that a small phase II trial of 26 patients with a 48-month follow-up of 48 months showed that preoperative acceptance The overall survival for chemotherapy was 68% compared to 30% to 40% for patients who received chemotherapy alone without chemotherapy. Dr. Siefker-Radtke explained that the preliminary study was mainly based on a retrospective data from an earlier study, which confirmed that the prognosis of patients with postoperative small cell bladder cancer who received chemotherapy was significantly better than that of chemotherapy alone.